Sunflower Pharmaceutical Group Co Ltd operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Sunflower Pharmaceutical Group Co Ltd with three other
companies in this sector in China:
sales of 3.73 billion Chinese Renmimbi [US$595.22 million]
Shenzhen Salubris Pharmaceuticals Co Ltd
(4.15 billion Chinese Renmimbi [US$662.07 million]
of which 82%
was Preparation), and
Zhangzhou Pientzehuang Pharmaceutical Ltd
(3.71 billion Chinese Renmimbi [US$591.97 million]
of which 51%
was Pharmaceutical Business).
Sunflower Pharmaceutical Group Co Ltd reported sales of 3.85 billion Chinese Renmimbi (US$614.41 million)
December of 2017.
increase of 14.7%
versus 2016, when the company's sales were 3.36 billion Chinese Renmimbi.
Sales at Sunflower Pharmaceutical Group Co Ltd have increased during each of the previous five years
(and since 2012, sales have increased a total of 118%).
Sales of Other saw an increase
that was more than double the company's growth rate: sales were up
39.0% in 2017, from
74.04 million Chinese Renmimbi to 102.92 million Chinese Renmimbi.